- Raw materials
- Hormonal Agents
- Progestagens
- Apolizumab
Mpa (Apolizumab) API Manufacturers & Suppliers
0 verified results
Total market transparency
Supplier trade data access
Buyer / supplier flow comparison
Commercial-scale Suppliers
Join our notification list by following this page.
Click the button below to find out more
Click the button below to switch over to the contract services area of Pharmaoffer.
Total market transparency
Supplier trade data access
Buyer / supplier flow comparison
Apolizumab | CAS No: 267227-08-7 | GMP-certified suppliers
A medication that targets hematologic malignancies and certain solid tumors by selectively eliminating malignant B cells through immune-mediated cytotoxic mechanisms.
Therapeutic categories
Primary indications
- Investigated for use/treatment in lymphoma (non-hodgkin's), leukemia (lymphoid), and solid tumors
Product Snapshot
- Apolizumab is an investigational monoclonal antibody formulation
- It is primarily targeted for use in hematologic malignancies, including non-Hodgkin's lymphoma and lymphoid leukemia, as well as solid tumors
- Currently, Apolizumab is in the investigational phase and has not received FDA or EMA approval
Clinical Overview
The mechanism of action of apolizumab involves selective binding to the 1D10 antigen-positive B cells. Upon binding, it mediates cytotoxic effects through complement activation, antibody-dependent cell-mediated cytotoxicity (ADCC), and induction of apoptosis. These pathways collectively contribute to the elimination of malignant B cells in vitro.
Pharmacodynamic data remain limited, reflecting its investigational status. Absorption, distribution, metabolism, and excretion (ADME) characteristics typical of humanized monoclonal antibodies are anticipated, involving distribution primarily in the vascular and interstitial compartments and metabolism via proteolytic catabolism to peptides and amino acids. No comprehensive clinical pharmacokinetic profile for apolizumab has been established.
Safety considerations derive from its action on normal B-cell populations, which may predispose to immunosuppression and increased risk of infection. As an investigational agent, comprehensive toxicity data, including immunogenicity and off-target effects, are yet to be fully characterized.
Apolizumab is classified within the amino acids, peptides, and proteins category, specifically as a humanized monoclonal antibody and immunoglobulin. It is not approved for clinical use and is primarily encountered in research and clinical trial settings.
For API sourcing, ensuring compliance with current Good Manufacturing Practices (cGMP) and rigorous quality control is essential given the complexity of monoclonal antibody production. Verification of antibody integrity, purity, and consistent bioactivity is critical to support investigational use and future clinical development.
Identification & chemistry
| Generic name | Apolizumab |
|---|---|
| Molecule type | Biotech |
| CAS | 267227-08-7 |
| UNII | G88KCP51RE |
| DrugBank ID | DB06467 |
Pharmacology
| Summary | Apolizumab is a humanized monoclonal antibody targeting the 1D10 polymorphic determinant on the HLA-DR beta chain, expressed on both normal and malignant B cells. It mediates antitumor effects through complement-dependent cytotoxicity, antibody-dependent cell-mediated cytotoxicity, and induction of apoptosis in 1D10-positive B cells. The agent has been investigated for therapeutic applications in non-Hodgkin's lymphoma, lymphoid leukemia, and certain solid tumors. |
|---|---|
| Mechanism of action | Apolizumab is a humanized monoclonal antibody directed against 1D10, a polymorphic determinant on the HLA-DR beta chain that is expressed on normal and neoplastic B cells. Apolizumab induces complement-mediated cytotoxicity, antibody-dependent cell-mediated cytotoxicity, and apoptosis of 1D10 antigen-positive B cells in vitro. |
Formulation & handling
- Apolizumab is a biotech-derived investigational agent typically formulated for parenteral administration.
- Due to its proteinaceous nature, Apolizumab requires careful handling to maintain structural stability.
- Storage conditions should protect the solid form from moisture and temperature variations to preserve potency.
Regulatory status
Apolizumab is a type of Other substances
The pharmaceutical industry encompasses a diverse range of active pharmaceutical ingredients (APIs) that are used in the production of various medications. One category of APIs is known as other substances. This category includes substances that do not fall under the conventional classifications such as antibiotics, analgesics, or antihypertensives.
Other substances in pharmaceutical APIs consist of a broad array of chemical compounds with unique properties and applications. These substances play a crucial role in the formulation and development of specialized medications, catering to specific therapeutic needs. The category encompasses various substances like excipients, solvents, stabilizers, and pH adjusters.
Excipients are inert substances that aid in the manufacturing process and enhance the stability, bioavailability, and patient acceptability of pharmaceutical formulations. Solvents are used to dissolve other ingredients and facilitate their incorporation into the final product. Stabilizers ensure the integrity and shelf life of medications by preventing degradation or chemical changes. pH adjusters help maintain the desired pH level of a formulation, which can influence the drug's efficacy and stability.
Pharmaceutical manufacturers carefully select and incorporate specific other substances into their formulations, adhering to regulatory guidelines and quality standards. These substances undergo rigorous testing and evaluation to ensure their safety, efficacy, and compatibility with the desired pharmaceutical product. By employing other substances in API formulations, pharmaceutical companies can optimize drug delivery, improve patient compliance, and enhance therapeutic outcomes.
In summary, the other substances category of pharmaceutical APIs comprises a diverse range of chemicals, including excipients, solvents, stabilizers, and pH adjusters. These substances contribute to the formulation, stability, and performance of medications, enabling pharmaceutical manufacturers to develop specialized products that meet specific therapeutic requirements.
